Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex

NCT04922554 is registered in ClinicalTrials.gov with Paratek Pharmaceuticals Inc as lead sponsor.

NCT NCT04922554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04922554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex
Lead sponsor
Paratek Pharmaceuticals Inc
Phase
Phase 2
Overall status
Completed
Start date
October 15, 2021
Completion date
July 17, 2024
Enrollment
66 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

mycobacterium abscessus infection, mycobacterium infections, nontuberculous, nontuberculous mycobacterial lung disease, nontuberculous mycobacterial pulmonary infection